TREATMENT OF INTOXICATIONS WITH RENAL REPLACEMENT THERAPY Timothy E. Bunchman Professor Pediatric Nephrology & Transplantation.

Slides:



Advertisements
Similar presentations
RRT and Intoxications Timothy E Bunchman. Case Study-1 17 y/o female with poly pharmacy overdose including risperidone, stratttera and long acting Lithium.
Advertisements

TREATMENT OF INTOXICATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY
IMPLEMENTATION & USE of CRRT in PEDIATRIC INTOXICATIONS Patrick D. Brophy MD University of Michigan Pediatric Nephrology.
Renal Replacement Therapy Options for Children
Pediatric CRRT: Terminology and Physiology
Hemodiafiltration and Hemofiltration
CVVH vs CVVHD Does it Matter?
So how do I dose this drug “X” Timothy E Bunchman
Continuous Veno-venous Hemodiafiltration Therapy for Acute Decompensation with Cerebral Edema in Maple Syrup Urine Disease Joshua J. Zaritsky M.D., Julian.
DIALYSIS? HEMOPERFUSION? What’s up with enhanced elimination of drugs?
MANAGEMENT OF CONTINUOUS HEMODIALYSIS
Extracorporeal techniques in poisoning Ben Creagh-Brown SHO Anaesthetics October 2003.
Case Study in RRT in In Born Error of Metabolism Timothy E. Bunchman Pediatric Nephrology & Transplantation VCU School of Medicine
Dr Umut Selda Bayrakçı Yıldırım Beyazıt University, Dept of Pediatric Nephrology, Ankara, Turkey * Basics of CRRT Terminology.
RENAL REPLACEMENT THERAPY
Drug Kinetics and CRRT: Parameters and Principles Morgan R. Cole, Pharm.D., BCPS Manager, HDVCH Pharmacy Services Clinical Pharmacy Specialist, Pediatric.
Anatomy and Physiology of Peritoneal Dialysis
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Types of Dialysis  1. Hemodialysis  2. Peritoneal dialysis – just be aware of it’s existence.
Iron Toxicity. Overview Principle of the disease Clinical features Diagnosis management.
HEMODIALYSIS DIALYZER
Hepatic Support Therapies Patrick Brophy MD CS Mott Children’s Hospital Pediatric Nephrology, Transplantation and Dialysis.
Md.Kausher ahmed Electrical department. Biomedical engineering Code:6875.
Dose Adjustment in Renal and Hepatic Disease
Hepatic Failure, intoxication and Hemofiltration Timothy E Bunchman Professor Pediatric Nephrology & Transplantation.
Lithium Poisoning: when is hemodialysis indicated?
Hemodialysis and Hemofiltration in Pediatrics: An Approach to Intoxication Karen Papez MD University of Michigan Pediatric Nephrology, Dialysis & Transplantation.
Toxicokinetics is not rocket science Kent R. Olson, MD Medical Director, SF Division California Poison Control System.
PCRRT PRESCRIPTIONS in ARF Patrick D. Brophy MD University of Michigan Pediatric Nephrology.
Experiences with plasmapheresis in our pediatric dialysis unit L. Koster-Kamphuis, E. Cornelissen, E. Levtchenko, N. van de Kar Dept. of Pediatric Nephrology.
Among important toxicological principles that are applied in evaluating the poisoned individual are  Exposure and aspects related to reducing absorption.
Renal Replacement Therapy in Intoxications Maria Ferris, MD, MPH, PhD University of North Carolina Kidney Center Chapel Hill, North Carolina USA 7/17/2015.
Methods of gastric decontamination: 1-single dose activated charcoal. 2-multiple dose activated charcoal. 3-gastric aspiration and lavage. 4-whole bowel.
Honorary Clinical Lecturer Kings College London
Excessive fluid is not needed: So why is Dr. Durward so wasteful? Timothy E Bunchman MD Professor & Director Pediatric Nephrology
Sustained Low Efficiency Dialysis
APPLICATION OF INDIVIDUALIZED BAYESIAN UREA KINETIC MODELING TO PEDIATRIC HEMODIALYSIS Olivera Marsenic, Athena Zuppa, Jeffrey S. Barrett, Marc Pfister.
Clinical Pharmacokinetics of Lithium Dr. Muslim Suardi, MSi., Apt. School of Pharmacy, Faculty of Science University of Andalas 2004.
Renal Replacement Therapy for Intoxications Timothy E. Bunchman Pediatric Nephrology & Transplantation DeVos Children’s Hospital Grand Rapids, MI (thanks.
Common Terminology Used and Physiology in CRRT Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital Seattle, WA.
PCRRT Multi-Center Registry Data Effective April 1, 2002 Multi-Center Pediatric CRRT Registry Stuart L. Goldstein, MD Assistant Professor of Pediatrics.
Progression of Chronic Kidney Disease
Clinical Pharmacokinetic Equations and Calculations
Dosing of Anti-Fungal agents on CRRT Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children’s Hospital of Richmond.
PCRRT Tûr'mə-nŏl'ə-jē Helen Currier BSN, RN, CNN Assistant Director, Renal/Pheresis Texas Children’s Hospital Houston, Texas.
Hepatic Failure and Hemofiltration Timothy E Bunchman Professor Pediatric Nephrology & Transplantation.
DRUG TREATMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC RENAL DISEASE Presented by Ri.
Foundation Knowledge and Skills
DEPARTMENT NAME Jennifer L. Morris, PharmD, BCPS Clinical Pharmacy Specialist – Pediatric Critical Care April 14, 2016 MEDICATION CONSIDERATIONS IN EXTRACORPOREAL.
BY RAFAT RABEEYA UNDER THE GUIDANCE OF MR.ARUN KUMAR.J.M.
Nephrology Specialist at New Mansoura General Hospital
Spotlight on general principles of hemodialysis
Chief Pediatric Nephrology Nemours/A.I. duPont Hospital for Children
بسم الله الرحمن الرحيم Enhanced Elimination & Antidote
Intoxication.
Devices use for Neonatal AKI
Prescriptions in CRRT Timothy E Bunchman MD Professor & Director
Vascular Access and Infused Fluids for Pediatric CRRT
Anticonvulsants: Valproic acid
Pharmacokinetics & Drug Dosing
Andrew Durward St Thomas NHS Foundation Trust Orlando 2017 CRRT IN AKI.
Pediatric CRRT Terminology
Renal replacement therapy
Basics of CRRT: Terminology
Children’s Memorial Hospital Northwestern University
Case 20 kg child with sepsis and oliguria on norepinephrine with a BP of 95/45 Vent at 70% FIO2 and a PEEP of 8 FO at 15% K of 6 meq/dl and a BUN of 100.
Joachim Böhler, M.D., Johannes Donauer, Frieder Keller 
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Role of r.r.t in toxicology modalities and indications
Presentation transcript:

TREATMENT OF INTOXICATIONS WITH RENAL REPLACEMENT THERAPY Timothy E. Bunchman Professor Pediatric Nephrology & Transplantation

INTRODUCTION 2.2 million reported poisonings (1998) 67% in pediatrics Approximately 0.05% required extracorporeal elimination Primary prevention strategies for acute ingestions have been designed and implemented (primarily with legislative effort) with a subsequent decrease in poisoning fatalities

Poison Management DECONTAMINATION/TREATMENT OPTIONS FOR OVERDOSE Standard Airway, Breathing and Circulatory measures take precedent Oral Charcoal Bowel Cleansing Regimens Antidotes IV or PO when applicable IV Hydration

Extracorporeal Methods Peritoneal Dialysis Hemodialysis Hemofiltration Charcoal hemoperfusion Considerations Volume of Distribution (Vd)/compartments molecular size protein/lipid binding solubility

DistributionRe-distribution INPUTINPUT ELIMINATION

GENERAL PRINCIPLES kinetics of drugs are based on therapeutic not toxic levels (therefore kinetics may change) choice of extracorporeal modality is based on availability, expertise of people & the properties of the intoxicant in general Each Modality has drawbacks It may be necessary to switch modalities during therapy (combined therapies inc: endogenous excretion/detoxification methods)

INDICATIONS >48 hrs on vent ARF Impaired metabolism high probability of significant morbidity/mortality progressive clinical deterioration INDICATIONS severe intoxication with abnormal vital signs complications of coma prolonged coma intoxication with an extractable drug

PERITONEAL DIALYSIS 1st done in 1934 for 2 anuric patients after sublimate poisoning (Balzs et al; Wien Klin Wschr 1934;47:851 ) Allows diffusion of toxins across peritoneal membrane from mesenteric capillaries into dialysis solution within the peritoneal cavity limited use in poisoning (clears drugs with low Mwt., Small Vd, minimal protein binding & those that are water soluble) alcohols, NaCl intoxications, salicylates

HEMODIALYSIS optimal drug characteristics for removal: relative molecular mass < 500 water soluble small Vd (< 1 L/Kg) minimal plasma protein binding single compartment kinetics low endogenous clearance (< 4ml/Kg/min) (Pond, SM - Med J Australia 1991; 154: )

Intoxicants amenable to Hemodialysis vancomycin (high flux) alcohols diethylene glycol methanol lithium salicylates

Ethylene Glycol Intoxication Rx with Hemodialysis Duration of Rx (hrs) Mg/ml (> 30 mg/ml toxic)

Vancomycin clearance High efficiency dialysis membrane Time of therapy Vanc level (mic/dl) Rx Rebound

High flux hemodialysis for Carbamazine Intoxication Rx Hrs from time of ingestion Mic/ml

CHARCOAL HEMOPERFUSION optimal drug characteristics for removal: Adsorbed by activated charcoal small Vd (< 1 L/Kg) single compartment kinetics protein binding minimal (can clear some highly protein bound molecules) low endogenous clearance (< 4ml/Kg/min) (Pond, SM - Med J Australia 1991; 154: )

Intoxicants amenable to Charcoal Hemoperfusion Carbamazepine phenobarbital phenytoin theophylline paraquat

HEMOFILTRATION optimal drug characteristics for removal: relative molecular mass less than the cut-off of the filter fibres (usually < 40,000) small Vd (< 1 L/Kg) single compartment kinetics low endogenous clearance (< 4ml/Kg/min) (Pond, SM - Med J Australia 1991; 154: )

Continuous Detoxification methods CAVHF, CAVHD, CAVHP, CVVHF, CVVHD, CVVHP Indicated in cases where removal of plasma toxin is then replaced by redistributed toxin from tissue Can be combined with acute high flux HD

Serum half-life (hr) Valproic Acid Total Unbound Total Baseline SievingCoefficient* CVVHD CVVHD Albumin Albumin Hemofiltration

Carbamazine Clearance Natural Decay Clearance with Albumin Dialysis Askenazi et al, Pediatrics 2004

Hours LimEq/LLimEq/L CVVHD following HD for Lithium poisoning HD started CVVHD started CT-190 (HD) Multiflo-60 both patients BFR-pt #1 200 ml/min HD & CVVHD -pt # ml/min HD & 200 ml/min CVVHD PO 4 Based dialysate at 2L/1.73m 2 /hr Li Therapeutic range mEq/L

Intoxicants amenable to Hemofiltration vancomycin methanol procainamide hirudin thallium lithium methotrexate

Plasmapheresis / Exchange Blood Transfusions Plasmapheresis (Seyffart G. Trans Am Soc Artif Intern Organs 1982; 28:673) role in intoxication not clearly established most useful for highly protein bound agents Exchange Blood Transfusions Pediatric experience > than adult Methemoglobinemia overall very limited role in poisoning

OTHER ISSUES Optimal prescription biocompatible filters - may increase protein adsorption maximal blood flow rates (ie good access) physiological solution (ARF vs non ARF) ? Removal of antidote counter-current D maximal removal of toxins

Novel Approaches to facilitating intoxicant removal during hemofiltration Addition of albumin to dialysate Enhancement of Valproic Acid removal during CVVHD by the addition of albumin to dialysate A 6-1/2 month old infant was hospitalized with a serum valproic acid level of 1043 mcg/mL. He received CVVHD (blood flow 80 mL/min; prefilter replacement fluid: 400mL/hr; dialysate: 450 mL/hr) without and with albumin 45 gm/L) in the dialysate. Serial serum levels were obtained before and during dialysis. (PRISMA- M60) V Chadha et al. pCRRT- Orlando 2002 Albumin Hemofiltration